Aman Chauhan: Rare and aggressive cancer requires funding to develop better treatments
Aman Chauhan shared on X:
“Cancer can be an especially cruel and indiscriminate illness, claiming the lives of individuals with immense talent and promise, such as a young and upcoming movie director Sean.
It’s heartbreaking when a vibrant life is cut short by high-grade neuroendocrine cancer, a particularly aggressive form of cancer. Raising awareness for high-grade neuroendocrine cancer is crucial.
This rare and aggressive cancer requires more research and funding to develop better treatments and find a cure. By supporting institutions like the Sylvester Comprehensive Cancer Center, we can contribute to the fight against this devastating disease.
The center is dedicated to rare cancer research, treatment, and education, providing hope and support to patients and their families.
Consider donating to Sylvester Neuroendocrine Cancer Research. Every effort counts in the battle against cancer, and together, we can make a difference.”
Source: Aman Chauhan/X
Dr. Aman Chauhan leads the University of Miami Neuroendocrine Cancer Program and focuses on treating neuroendocrine tumors (NETs), including carcinoid tumors and high-grade neuroendocrine carcinomas.
He is the national principal investigator for several investigator-initiated neuroendocrine cancer theranostics clinical trials. Dr. Chauhan serves on AJCC and ASCO NET guideline committees, and is an active member of the NANETS communication committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023